Back

Cardiotoxicity and immune checkpoint inhibitors: a heartfelt myth or the real deal?

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Interventions to improve outcomes in cardio-oncology Cardio-Oncology HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Sofia Esteves

Centro Hospitalar Universitário Lisboa Norte, Lisbon (Portugal)

4 More presentations in this session

Presentation thumbnail
Cardioprotective strategies and outcomes in cancer therapy-related cardiac dysfunction: insights from a single-center study
Doctor I. Martins Moreira (Vila Real, PT)
Abstract Slides Video
Presentation thumbnail
Cardiovascular disease and its association with outcomes in cancer patients treated with immune checkpoint inhibitors
Doctor M. Slieman (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after two years of observation.
Doctor S. Maragkoudakis (Chania, GR)
Abstract Slides Video
Presentation thumbnail
Impact of cancer therapies and cardiovascular risk factors on new-onset heart failure: insights from a cardio-oncology cohort
Doctor I. Araujo (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Interventions to improve outcomes in cardio-oncology

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Immune checkpoint inhibitor associated myocarditis - lessons from a case series
thumbnail
Congress Presentation
Comprehensive analysis of risk factors for the severity of immune checkpoint inhibitor-associated myocarditis in cancer patients
thumbnail
Congress Presentation
Cardiovascular risks of PD1 inhibitor therapy in cancer: impact of prior ischemic events on heart failure - a retrospective cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources